Acute Myeloid Leukemia Market worth $17.1 billion by 2024
According to the new market research report the acute myeloid leukemia market is projected to reach USD 17.1 billion by 2024 from USD 12.3 billion in 2019, at a CAGR of 6.8% during the forecast period. Ask For PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223 Growth in this market is largely driven by the growing geriatric population and the introduction of innovative therapies for the treatment of leukemia. However, complexities in manufacturing serve as a key restraint to market growth. The major players in the acute myeloid leukemia market are Sanofi (France), AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland), F. Hoffmann-La Roche (Switzerland), Pfizer (US), Amgen (US), Takeda Pharmaceutical (Japan), Gilead Sciences (US), and Celgene (US). Product launches and acquisitions are the key growth strategies adopted by most players in this market. Based on treatment type, the acute myeloid leukemia market is bifurcated into chemotherapy and...